



FIMECS Presents at the Discovery Europe 2023

Kanagawa, Japan, 3 June 2023 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Yusuke Tominari, Ph.D., Co-founder, CEO of FIMECS, will make a presentation at the Discovery Europe 2023 (6-7 June 2023 in Berlin, Germany) as a keynote speaker. Title is “Function-first strategy that enables efficient and productive generation of degraders with identification of novel E3 ligase binders”. In this presentation, improvement of the RaPPIDS™ platform for expanding the landscape of E3 ligases by function-first approach that make degrader discovery more efficient will be introduced. The conference is one of the annual international conferences organized by Oxford Global, also co-located with Neuroscience Drug Development Europe 2023, and more than 400 people will participate in the conferences.

For more information: <https://www.oxfordglobal.co.uk/discovery-series/>

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. <https://www.fimecs.com/eng/>

About RaPPIDS™

RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

###

FIMECS, Inc. Media and Investor Contact:

FIMECS, Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

Tel: +81-466-96-0261

Email: info@fimecs.com